Shandong Sito Bio-technology Co., Ltd.

Equities

300583

CNE100002F36

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-05-16 EDT 5-day change 1st Jan Change
14.26 CNY -1.25% Intraday chart for Shandong Sito Bio-technology Co., Ltd. -8.53% -27.91%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shandong Sito Bio-technology Gets European Suitability Certification for Rhinitis Nasal Spray MT
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shandong Sito Bio-Technology Co., Ltd. Appoints Kang Li as Independent Director CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shandong Sito Bio-technology in Talks to Buy 60% of Local Steroid Maker for 46 Million Yuan MT
Shandong Sito Bio-technology Co., Ltd. agreed to acquire 60% stake in Yingu Pharmaceutical Co., Ltd. from Yingu Holding Group for approximately CNY 460 million. CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shandong Sito Bio-Technology Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 28 June 2023 CI
Shandong Sito Bio-technology Co., Ltd. Proposes Final Cash Dividend for 2022 CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shandong Sito Bio-technology Co., Ltd. announced that it has received CNY 261.590392 million in funding from a group of investors CI
Sito Bio-technology Selling 300 Million Yuan Shares to Fund New Factory MT
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shandong Sito Bio-Technology Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 05 July 2022 CI
Shandong Sito Bio-technology Co., Ltd. announced that it expects to receive CNY 298.0822 million in funding from a group of investors CI
Shandong Sito Bio-technology Co., Ltd. Approves Cash Dividend for the Year 2021 CI
Shandong Sito Bio-Technology Co., Ltd. Proposes Final Dividend for 2021 CI
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Shandong Sito Bio-technology Co., Ltd. cancelled the transaction announced on July 16, 2021 CI
Junlanghui Enterprise Management Partnership (Limited Partnership) signed a share transfer agreement to acquire a 5% stake in Shandong Sito Bio-technology Co., Ltd. (SZSE : 300583) from Shandong Runxin Investment Co., Ltd. for approximately CNY 140 million. CI
Chinese cities ease home purchase down-payments to reignite demand RE
Shandong Sito Bio-technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Shandong Sito Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Chart Shandong Sito Bio-technology Co., Ltd.
More charts
Shandong Sito Bio-technology Co Ltd is a company that provides raw materials for pharmaceutical companies. The Company operates three product segments. The Steroid Raw Materials segment is engaged in the manufacturing of steroid raw materials using genetic engineering technology and microbial transformation technology, such as androstenedione, androstenedione, 9-hydroxyandrostenedione, hydroxyprogesterone and so on. The Company also operates Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment through its subsidiary.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.26
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300583 Stock
  4. News Shandong Sito Bio-technology Co., Ltd.
  5. Sito Bio-technology Selling 300 Million Yuan Shares to Fund New Factory
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW